by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 weeks, according to the phase 1 randomised controlled trial. The drug, which works by blocking HIV from entering and multiplying in human...
by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn’s Disease (CD) patients who are all MAP-positive, and will… The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in...
